Nakamura, M., Aoyama, T., Ishibashi, K., Tsuji, A., Takinishi, Y., Shindo, Y., . . . Mishima, H. (2016). Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother Pharmacol.

Nakamura, Masato, Toru Aoyama, Keiichiro Ishibashi, Akihito Tsuji, Yasutaka Takinishi, Yoshiaki Shindo, Junichi Sakamoto, Koji Oba, och Hideyuki Mishima. "Randomized Phase II Study of Cetuximab Versus Irinotecan and Cetuximab in Patients With Chemo-refractory KRAS Codon G13D Metastatic Colorectal Cancer (G13D-study)." Cancer Chemother Pharmacol 2016.

Nakamura, Masato, et al. "Randomized Phase II Study of Cetuximab Versus Irinotecan and Cetuximab in Patients With Chemo-refractory KRAS Codon G13D Metastatic Colorectal Cancer (G13D-study)." Cancer Chemother Pharmacol 2016.